Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

- Login
- Sign Up

Desmetramadol featured today in new article by Research Outreach

Syntrix Pharmaceuticals > News > Desmetramadol featured today in new article by Research Outreach

Desmetramadol featured today in new article by Research Outreach

Desmetramadol featured today in new article by Research Outreach

December 17, 2018 Syntrix

By Syntrix

December 17, 2018

Desmetramadol featured today in new article by Research Outreach entitled, “Moving beyond dangerous opioids for pain: Syntrix creates new drug for safer pain relief”.

0

Shares

About Syntrix

More by Syntrix

Related Articles

Syntrix to Collaborate with NCI to Study SX-682 – Cooperative Research and Development Agreement (CRADA) Assesses SX-682 Alone and In Various Combinations

June 16, 2017 - by Syntrix

Syntrix Publication in Bioorganic & Medicinal Chemistry Letters

Syntrix Publication in Bioorganic & Medicinal Chemistry Letters

April 23, 2015 - by Syntrix

Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor

April 7, 2016 - by Syntrix

Syntrix Pharmaceuticals
215 Clay Street NW
Suite B-5
Auburn, WA 98001

©2024 All Rights Reserved

NIH Required Policy for Managing Conflicts of Significant Financial Interest

Recent Articles

New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies

Home
Team
Research
Therapy Pipeline
- Pain
- Immuno-Oncology
Apply

Get in touch

TEL: 253-833-8009
FAX: 253-833-8127 email: info@syntrixbio.com